Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome
- PMID: 26114369
- DOI: 10.3928/00904481-20150611-09
Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome
Abstract
Systemic juvenile idiopathic arthritis (sJIA) is characterized by a large range of extra-articular manifestations in addition to joint inflammation. The child with sJIA usually presents with a spiking fever pattern, evanescent rash, and arthralgias/arthritis. Other features often present are lymphadenopathy, hepatosplenomegaly, and polyserositis. The systemic manifestations are frequently more prominent and severe than the arthritis. Laboratory studies reflect systemic inflammation with significant anemia, and elevation of acute phase reactants, platelets, and white blood cell count. Ferritin level is often strikingly high. The treatment of sJIA has evolved over the past decade with the improved understanding of the role of specific inflammatory cytokines in this disease. The medications employed to treat sJIA directly inhibit the actions of these cytokines. A major cause of morbidity and mortality of children with sJIA is the development of macrophage activation syndrome, which can cause unremitting fevers, pancytopenia, coagulopathy, and hepatic dysfunction.
Copyright 2015, SLACK Incorporated.
Similar articles
-
Systemic onset juvenile idiopathic arthritis: a single center experience.Turk J Pediatr. 2019;61(6):852-858. doi: 10.24953/turkjped.2019.06.005. Turk J Pediatr. 2019. PMID: 32134578
-
Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.Rheumatol Int. 2016 Oct;36(10):1421-9. doi: 10.1007/s00296-016-3545-9. Epub 2016 Aug 10. Rheumatol Int. 2016. PMID: 27510530
-
A MASsive attack: a pediatric case of macrophage activation syndrome complicated by DIC as an onset of systemic juvenile idiopathic arthritis successfully treated with anakinra and review of the literature.Rheumatol Int. 2024 Nov;44(11):2607-2612. doi: 10.1007/s00296-024-05570-z. Epub 2024 Mar 19. Rheumatol Int. 2024. PMID: 38502236 Review.
-
Systemic Juvenile Idiopathic Arthritis.Pediatr Clin North Am. 2018 Aug;65(4):691-709. doi: 10.1016/j.pcl.2018.04.005. Pediatr Clin North Am. 2018. PMID: 30031494 Review.
-
Macrophage activation syndrome in an inadequately treated patient with systemic onset juvenile idiopathic arthritis.Kathmandu Univ Med J (KUMJ). 2009 Oct-Dec;7(28):411-3. doi: 10.3126/kumj.v7i4.2764. Kathmandu Univ Med J (KUMJ). 2009. PMID: 20502084
Cited by
-
Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis.Int J Mol Sci. 2022 Apr 12;23(8):4268. doi: 10.3390/ijms23084268. Int J Mol Sci. 2022. PMID: 35457086 Free PMC article. Review.
-
Inhibitory effects of andrographolide on activated macrophages and adjuvant-induced arthritis.Inflammopharmacology. 2018 Apr;26(2):447-456. doi: 10.1007/s10787-017-0375-7. Epub 2017 Jul 22. Inflammopharmacology. 2018. PMID: 28735448
-
Identification of Key Biomarkers and Immune Infiltration in Systemic Juvenile Idiopathic Arthritis by Integrated Bioinformatic Analysis.Front Mol Biosci. 2021 Jul 14;8:681526. doi: 10.3389/fmolb.2021.681526. eCollection 2021. Front Mol Biosci. 2021. PMID: 34336925 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous